SRT3 Stock Overview
Provides bioprocess solutions and lab products and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sartorius Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €214.60 |
| 52 Week High | €383.70 |
| 52 Week Low | €199.50 |
| Beta | 0.93 |
| 11 Month Change | -19.38% |
| 3 Month Change | -8.87% |
| 1 Year Change | -22.83% |
| 33 Year Change | -61.77% |
| 5 Year Change | 13.73% |
| Change since IPO | 346.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| SRT3 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -6.5% | -5.2% | -0.5% |
| 1Y | -22.8% | 2.8% | 8.3% |
Return vs Industry: SRT3 underperformed the German Life Sciences industry which returned 2.8% over the past year.
Return vs Market: SRT3 underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| SRT3 volatility | |
|---|---|
| SRT3 Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: SRT3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SRT3's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1870 | 13,762 | Joachim Kreuzburg | www.sartorius.com |
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products.
Sartorius Aktiengesellschaft Fundamentals Summary
| SRT3 fundamental statistics | |
|---|---|
| Market cap | €13.43b |
| Earnings (TTM) | €77.20m |
| Revenue (TTM) | €3.32b |
191.9x
P/E Ratio4.5x
P/S RatioIs SRT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRT3 income statement (TTM) | |
|---|---|
| Revenue | €3.32b |
| Cost of Revenue | €1.82b |
| Gross Profit | €1.50b |
| Other Expenses | €1.43b |
| Earnings | €77.20m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 28, 2025
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 45.22% |
| Net Profit Margin | 2.32% |
| Debt/Equity Ratio | 115.4% |
How did SRT3 perform over the long term?
See historical performance and comparison